Regencell Stock Surges 280% After 38-for-1 Split, Market Cap Nears $300B

Regencell Bioscience Holdings, a Hong Kong-based biotech company, has seen its stock price surge over threefold in a single day, propelling its market capitalization to nearly 300 billion dollars. The company, which focuses on developing traditional Chinese medicine therapies for conditions such as Attention Deficit Hyperactivity Disorder (ADHD) and autism, implemented a 38-for-1 stock split, contributing to a 280% increase in its stock price.

Regencell's meteoric rise is part of a broader trend of speculative trading in international stocks. The company, which has been trading on the Nasdaq since 2021 under the ticker symbol "RGC," has seen its stock price increase by approximately 46,000% since the beginning of 2025. Despite having no revenue, Regencell's market capitalization now rivals that of well-established companies like Lululemon, Super Micro Computer, and Fifth Third Bancorp.

The stock split, which took effect on June 2, was described by Regencell as a measure to "enhance the liquidity of the company's common stock in the market, making it easier for investors to acquire." The company's CEO, Yat-Gai Au, controls 86.24% of the total issued shares, according to FactSet data.

Regencell's stock price surge coincides with increased public interest in alternative medicine, following the appointment of Robert F. Kennedy Jr. as the U.S. Secretary of Health and Human Services. Kennedy, a vaccine skeptic, has taken steps to halt routine vaccinations in the U.S. and recently dismissed all members of the advisory committee for the Centers for Disease Control and Prevention (CDC) that provided vaccine recommendations.

Despite the dramatic increase in its stock price, Regencell's therapies for ADHD and autism spectrum disorders remain largely unproven and untested. The company's core business revolves around proprietary Chinese medicine formulations developed in collaboration with traditional Chinese medicine practitioner Sik-Kee Au, who is also the father of Regencell's CEO. These formulations, which claim to target mild, moderate, and severe symptoms, are composed of natural ingredients such as detoxifying herbs, blood-activating herbs, and digestive herbs.

Regencell's latest patient case study, dated November 15, 2023, reported improvements in ADHD and autism symptoms among 28 patients who underwent a three-month treatment regimen. However, the company has not generated any revenue from its Chinese medicine formulations and has not applied for any regulatory approvals. According to its latest annual report, Regencell incurred net losses of 4.36 million dollars and 6.06 million dollars for the fiscal years ending June 2024 and June 2023, respectively.

Regencell's stock has been the subject of both enthusiasm and skepticism among retail traders. On social media platforms like Reddit, some users have described the stock as trading like a meme coin, with one user reporting a 50% drop in the stock price immediately after purchasing. Another user claimed to have made small profits by trading the stock daily. In May alone, the stock price surged by 1,360%.